Abstract:Objective: To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting lung tumor in order to improve the tissue distribution of paclitaxel in vivo, and to promote the safety and the anti-tumor efficacy of paclitaxel administration. Methods: The complex of arginine glycine-aspartic acid-e-amino hexanoic acid linker-palmitate (RGD-EACA-Pal) was synthesized by solid-phase synthesis method. The sterically stabilized liposome of paclitaxel (SSL-PTX) and the active lung cancer-targeting sterically stabilized liposome of paclitaxel (T-SSL-PTX) were prepared by thin film ultrasonication-dispersion method, respectively. The pharmacokinetics, tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol, SSL-PTX or T-SSL-PTX in tumor-bearing nude mice. The maximum tolerance doses (MTDs) of two different formulations of paclitaxel were determined in Kunming mice. Results: Transmission electron microscopy (TEM) image showed that both SSL-PTX and T-SSL-PTX shaped regularly round and dispersed uniformly, and these two particle sizes were (83.4±36.7) nm and (94.7±41.2) nm, respectively. The encapsulation efficiencies of both SSL-PTX and T-SSL-PTX were at or above 95%. In vivo, the circulation time of SSL-PTX or T-SSL-PTX was longer than taxol, and the pharmacokinetic parameters of SSL-PTX and T-SSL-PTX were similar. Tumor-targeting efficiency of T-SSL-PTX was better than that of SSL-PTX or taxol, as well as the tissue distribution of T-SSL-PTX in normal organs was at a relatively low level as compared with that of SSL-PTX or taxol, in contribution to RGD specifically targeting tumors. The MTDs of SSL-PTX and T-SSL-PTX were higher than that of taxol. Compared with SSL-PTX and taxol with the same dose of paclitaxel, the anti-tumor efficacy of T-SSL-PTX was improved significantly (P＜0.05); and the mice received T-SSL-PTX therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.Conclusion: The lung cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo. DOI:10.3781/j.issn.1000-7431.2011.03.004

Cell Uptake of Paclitaxel Solid Lipid Nanoparticles Modified by Cell-Penetrating Peptides in A549 Cells.

Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

[In Situ Rat Intestine Absorption of Paclitaxel-Loaded Solid Lipid Nanoparticles Modified with Cell-Penetrating Peptides].

Study on the ability of specific-binding peptide modified liposome loaded paclitaxel targeting A549 lung cancer stem cell

Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo

RGD and cell penetrating peptides co-modiifed paclitaxel loaded liposome inhibit the A549 cells

Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-co-glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells

Cancer Cell Membrane-Camouflaged Paclitaxel/plga Nanoparticles for Targeted Therapy Against Lung Cancer

[Uptake of Monostearin Solid Lipid Nanoparticles by A549 Cells].

Synthesis of Novel Conjugated Linoleic Acid (CLA)-Coated Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for the Delivery of Paclitaxel with Enhanced In Vitro Anti-Proliferative Activity on A549 Lung Cancer Cells

Enhanced Antiproliferative and Apoptosis Effect of Paclitaxel-Loaded Polymeric Micelles Against Non-Small Cell Lung Cancers

Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor

Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance

Efficacy of Dual-Functional Liposomes Containing Paclitaxel for Treatment of Lung Cancer

Improved Cytotoxicity of Paclitaxel Loaded in Nanosized Lipid Carriers by Intracellular Delivery

[In Vitro and in Vivo Study of Two Kinds of Long-Circulating Solid Lipid Nanoparticles Containing Paclitaxel].

Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.

Paclitaxel-loaded poly(Glycolide-co-εcaprolactone)-b-d-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer

New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation